United BioSource Corporation (UBC; Bethesda, MD) announced the aquisition of Cognitive Drug Research (CDR), whose automative cognitive assessment system is the most popular system of its kind in the world. It's been used in more than 1000 clinical trials, encompasses 50 different disease areas, and is validated in over 60 languages. In addition, CDR maintains the industry’s largest healthy subject, drug, and patient databases of cognitive effects.
“The premier evidence base, reliability, and global reach of the CDR System coupled with UBC’s validated rater training, assessment, and rater surveillance methods will provide an unprecedented opportunity for improved signal detection in the measurement of cognition and clinically subjective endpoints,” said Ethan Leder, Chief Exectuive Officer of UBC, in a company press release. “The addition of Professor Keith Wesnes, to the UBC scientific team and our integrated offerings will provide sponsor companies with the broadest, most seamless capabilities available.”
Professor Keith Wesnes founded CDR in 1986.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
Vabysmo Shows Significant Vision Improvement for Diabetic Macular Edema in Underrepresented Patients
October 22nd 2024Phase IV ELEVATUM trial results show that one year of treatment with Vabysmo significantly improved vision in underrepresented racial and ethnic groups with diabetic macular edema, supporting the drug's efficacy and safety across diverse populations.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Clesrovimab Shows Significant Reduction in RSV Infections, Hospitalizations in Infants
October 18th 2024Merck's investigational monoclonal antibody, clesrovimab, shows significant efficacy in reducing respiratory syncytial virus-related infections and hospitalizations in infants, with a favorable safety profile.